-
Sector Analysis
NewResistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Resistant Hypertension (RH) Marketed and Pipeline Drugs Report Overview Resistant Hypertension (RH) refers to high blood pressure (BP) that is above the target level in a patient. This occurs even when they are taking three different classes of antihypertensive medications concurrently. These medication classes typically include diuretics, long-acting calcium channel blockers, and renin-angiotensin system blockers (ACEs or ARBs). The Resistant Hypertension (RH) marketed, and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales...
-
Product Insights
Likelihood of Approval Analysis for Orthomyxoviridae Infections
Overview How likely is it that the drugs in Orthomyxoviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orthomyxoviridae Infections Overview The family Orthomyxoviridae is defined by viruses that have...
-
Product Insights
Likelihood of Approval Analysis for Mutational Disorders
Overview How likely is it that the drugs in Mutational Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mutational Disorders Overview Mutational disorders, alternatively termed genetic or genomic disorders, stem...
-
Product Insights
Likelihood of Approval Analysis for Paramyxoviridae Infections
Overview How likely is it that the drugs in Paramyxoviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paramyxoviridae Infections Overview The Paramyxoviridae family belongs to the order Mononegavirales, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Azercabtagene Zapreleucel in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azercabtagene Zapreleucel in Diffuse Large B-Cell Lymphoma Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Azercabtagene Zapreleucel in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azercabtagene Zapreleucel in Mantle Cell Lymphoma Drug Details: Azercabtagene...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Azercabtagene Zapreleucel in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azercabtagene Zapreleucel in Follicular Lymphoma Drug Details: Azercabtagene zapreleucel (PBCAR-0191)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Azercabtagene Zapreleucel in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azercabtagene Zapreleucel in Primary Mediastinal B-Cell Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azercabtagene Zapreleucel in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azercabtagene Zapreleucel in Non-Hodgkin Lymphoma Drug Details: Azercabtagene zapreleucel (PBCAR-0191)...
-
Product Insights
NewBorderline Personality Disorder (BPD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Borderline Personality Disorder (BPD) Clinical Trial Report Overview A total of 71 borderline personality disorder (BPD) clinical trials were conducted as of March 2024. The borderline personality disorder (BPD) clinical trial report provides a comprehensive understanding of the borderline personality disorder (BPD) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with...